宁神灵颗粒抗抑郁作用机制研究
|
摘要
目的:探讨宁神灵颗粒治疗抑郁的作用机制。方法:建立抑郁症大鼠模型,并口服给予宁神灵颗粒,HE染色观察大鼠脑组织海马形态学的病理变化,RT-pcr法观察大鼠脑组织多巴胺受体D2、CAMK2amRNA的变化。结果:成功复制大鼠抑郁模型,宁神灵组能明显改善大鼠脑组织海马区锥体细胞的形态变化;能明显提高脑组织中D2、CAMK2amRNA的表达。结论:宁神灵能够治疗抑郁症,其机制与调节脑内相关因子表达相关。
Objective:To explore the mechanism of Ningshenling Granule in the treatment of depression.Methods:The rat model of depression was established,and Ningshenling Granule was given orally.The morphological changes of hippocampus were observed by HE staining,and the changes of dopamine receptor D2 and CAMK2a mRNA were observed by RT-pcr.Result:Ningshenling group could significantly improve the morphological changes of pyramidal cells in hippocampus and the expressions of D2 and CAMK2a in brain tissue.Conclusion:Ningshenling can treat depression,and its mechanism is related to regulating the expression of related factors in the brain.
Objective:To explore the mechanism of Ningshenling Granule in the treatment of depression.Methods:The rat model of depression was established,and Ningshenling Granule was given orally.The morphological changes of hippocampus were observed by HE staining,and the changes of dopamine receptor D2 and CAMK2a mRNA were observed by RT-pcr.Result:Ningshenling group could significantly improve the morphological changes of pyramidal cells in hippocampus and the expressions of D2 and CAMK2a in brain tissue.Conclusion:Ningshenling can treat depression,and its mechanism is related to regulating the expression of related factors in the brain.
引文
1蔡萧君,王磊.糖尿病合并抑郁的中西医研究进展[J].黑龙江中医药,2018,1:100.
2吕兰兰,倪龙燕,闫伟,等.抑郁障碍量化治疗模式研究进展[J].国际精神病学杂志,2018,45(6):994-997.
3 Alberich S,Martínez-Cengotitabengoa M,López P.Efficacy and safety of ketamine in bipolar depression:A systematic review[J].Rev Psiquiatr Salud Ment,2017,10(2):104-112.
4 Ren W,Luan X,Zhang J,et al.Brain-derived neurotrophic factor levels and depression during methamphetaminewithdrawal[J].J Affective Disorders,2017,15(221):165-171.
5薛涛,邬丽莎,刘新民,等.抑郁症动物模型及评价方法研究进展[J].中国实验动物学报,2015,23(3):321-3256关宇鹏,王帅,孟宪生,等.大鼠抑郁模型的建立及其综合评价研究[J].亚太传统医药,2015,11(9):3-5.
7 Zannas AS,Wiechmann T,Gassen NC,et al.Genestress-epigenetic regulation of FKBP5:clinical and translational implications[J].Neuropsychopharmacology,2016,41(1):261-274.
8 Yang Y,Cui Y,Sang K,et al.Ketamine blocks bursting in the lateral habenula to rapidly relieve depression[J].Nature,2018,554(7692):317-322.
9 Mrazek DA,Hornberger JC,Altar CA,et al.A Review of the clinical,economic,and societal burden of treatment-resistant depression:1996-2013[J].Psychiatric Services,2014,65(8):977-987.
10 Song M,Martinowich K,Lee FS.BDNF at the synapse:why location matters[J].Molecular Psychiatry,2017,22(10):1370-1375.
11蔡萧君,王磊,吴超全,等.宁神灵对卒中后抑郁血浆IL-
1β、IL-2、IL-6和TNF-α影响的研究[J].黑龙江中医药,2017,4:2-5.
12 Missale C,Nash SR,Robinson SW,et al.Dopamine receptors:from structure to function[J].Physiological Reviews,1998,78:189-225.
13 Dunlop BW,Nemeroff CB.The role of dopamine in the pathophysiology of depression[J].Arch Gen Psychiatry,2007,64(3):327-337.
14 Gabriel F,Nils G,Theo R.The FKBP51glucocorticoid receptor co-chaperone:regulation,function,and implications in health and disease[J].International Journal of Molecular Sciences,2017,18(12):2614.
15 May HT,Horne BD,Knight S,et al.The associa-tion of depression at any time to the risk of death followingcoronary artery disease diagnosis[J].Eur Heart J QualCare Clin Outcomes,2017,10(4):296-302.
16 Koh TW,Bellen HJ.Synaptotagmin I,a Ca2+sensor for neurotransmitter release[J].Trends in Neurosciences,2003,26(8):413-422.
17陈旭,周晶晶,朱雪泉,等.抑郁障碍的自我管理体系研究[J].中国医刊,2017,4:81-84.
18刘世钰,何丹,赵亮,等.养心氏片抗抑郁作用的蛋白组学研究[J].中南药学,2018,16(5):599-600.
2吕兰兰,倪龙燕,闫伟,等.抑郁障碍量化治疗模式研究进展[J].国际精神病学杂志,2018,45(6):994-997.
3 Alberich S,Martínez-Cengotitabengoa M,López P.Efficacy and safety of ketamine in bipolar depression:A systematic review[J].Rev Psiquiatr Salud Ment,2017,10(2):104-112.
4 Ren W,Luan X,Zhang J,et al.Brain-derived neurotrophic factor levels and depression during methamphetaminewithdrawal[J].J Affective Disorders,2017,15(221):165-171.
5薛涛,邬丽莎,刘新民,等.抑郁症动物模型及评价方法研究进展[J].中国实验动物学报,2015,23(3):321-3256关宇鹏,王帅,孟宪生,等.大鼠抑郁模型的建立及其综合评价研究[J].亚太传统医药,2015,11(9):3-5.
7 Zannas AS,Wiechmann T,Gassen NC,et al.Genestress-epigenetic regulation of FKBP5:clinical and translational implications[J].Neuropsychopharmacology,2016,41(1):261-274.
8 Yang Y,Cui Y,Sang K,et al.Ketamine blocks bursting in the lateral habenula to rapidly relieve depression[J].Nature,2018,554(7692):317-322.
9 Mrazek DA,Hornberger JC,Altar CA,et al.A Review of the clinical,economic,and societal burden of treatment-resistant depression:1996-2013[J].Psychiatric Services,2014,65(8):977-987.
10 Song M,Martinowich K,Lee FS.BDNF at the synapse:why location matters[J].Molecular Psychiatry,2017,22(10):1370-1375.
11蔡萧君,王磊,吴超全,等.宁神灵对卒中后抑郁血浆IL-
1β、IL-2、IL-6和TNF-α影响的研究[J].黑龙江中医药,2017,4:2-5.
12 Missale C,Nash SR,Robinson SW,et al.Dopamine receptors:from structure to function[J].Physiological Reviews,1998,78:189-225.
13 Dunlop BW,Nemeroff CB.The role of dopamine in the pathophysiology of depression[J].Arch Gen Psychiatry,2007,64(3):327-337.
14 Gabriel F,Nils G,Theo R.The FKBP51glucocorticoid receptor co-chaperone:regulation,function,and implications in health and disease[J].International Journal of Molecular Sciences,2017,18(12):2614.
15 May HT,Horne BD,Knight S,et al.The associa-tion of depression at any time to the risk of death followingcoronary artery disease diagnosis[J].Eur Heart J QualCare Clin Outcomes,2017,10(4):296-302.
16 Koh TW,Bellen HJ.Synaptotagmin I,a Ca2+sensor for neurotransmitter release[J].Trends in Neurosciences,2003,26(8):413-422.
17陈旭,周晶晶,朱雪泉,等.抑郁障碍的自我管理体系研究[J].中国医刊,2017,4:81-84.
18刘世钰,何丹,赵亮,等.养心氏片抗抑郁作用的蛋白组学研究[J].中南药学,2018,16(5):599-600.